Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com..
BACKGROUND AND AIMS: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated.
MATERIALS AND METHODS: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis.
RESULTS: IBD patients considered numbered 44619: 21953 Crohn's disease [CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients: 99 CD [CD-K], 75 UC [UC-K]. Controls included 198 CD [CD-C], 150 UC [UC-C]. Cancer incidence in IBD was 3.9/1000, higher in CD (4.5/1000 [99/21,953]) than in UC (3.3/1000 [75/22,666]; p = 0.042). Cancers involved: digestive system [36.8%], skin [13.2%], urinary tract [12.1%], lung [8.6%], breast [8%], genital tract [6.9%], thyroid [4.6%], lymphoma [3.5%], others [6.3%]. In CD, penetrating behaviour and combined thiopurines and tumour necrosis factor alpha [TNFα] antagonists were risk factors for cancer overall: odds ratio [OR] (95% confidence interval [CI] 2.33 [1.01-5.47]); 1.97 [1.1-3.5]; and for extracolonic cancers 3.9 [1.56-10.1]; 2.15 [1.17-4.1], respectively. In UC, risk factors were pancolitis and disease-related surgery for cancer overall (OR: 2.52 [1.26-5.1]; 5.09 [1.73-17.1]); disease-related surgery for colorectal cancer [CRC] (OR 3.6 [1.0-12]); and extensive and left-sided vs distal UC for extracolonic cancers (OR: 2.55 [1.15-5.9]; 2.6 [1.04-6.6]), respectively.
CONCLUSIONS: In a multicentre study, penetrating CD and extensive UC were risk factors for cancer overall. Cancer incidence was higher in CD than in UC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 10(2016), 8 vom: 15. Aug., Seite 913-24 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Biancone, Livia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer risk |
|---|
| Anmerkungen: |
Date Completed 09.06.2017 Date Revised 09.06.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjw048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM258013532 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258013532 | ||
| 003 | DE-627 | ||
| 005 | 20231224184101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjw048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0860.xml |
| 035 | |a (DE-627)NLM258013532 | ||
| 035 | |a (NLM)26933032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Biancone, Livia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2017 | ||
| 500 | |a Date Revised 09.06.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND AND AIMS: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated | ||
| 520 | |a MATERIALS AND METHODS: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis | ||
| 520 | |a RESULTS: IBD patients considered numbered 44619: 21953 Crohn's disease [CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients: 99 CD [CD-K], 75 UC [UC-K]. Controls included 198 CD [CD-C], 150 UC [UC-C]. Cancer incidence in IBD was 3.9/1000, higher in CD (4.5/1000 [99/21,953]) than in UC (3.3/1000 [75/22,666]; p = 0.042). Cancers involved: digestive system [36.8%], skin [13.2%], urinary tract [12.1%], lung [8.6%], breast [8%], genital tract [6.9%], thyroid [4.6%], lymphoma [3.5%], others [6.3%]. In CD, penetrating behaviour and combined thiopurines and tumour necrosis factor alpha [TNFα] antagonists were risk factors for cancer overall: odds ratio [OR] (95% confidence interval [CI] 2.33 [1.01-5.47]); 1.97 [1.1-3.5]; and for extracolonic cancers 3.9 [1.56-10.1]; 2.15 [1.17-4.1], respectively. In UC, risk factors were pancolitis and disease-related surgery for cancer overall (OR: 2.52 [1.26-5.1]; 5.09 [1.73-17.1]); disease-related surgery for colorectal cancer [CRC] (OR 3.6 [1.0-12]); and extensive and left-sided vs distal UC for extracolonic cancers (OR: 2.55 [1.15-5.9]; 2.6 [1.04-6.6]), respectively | ||
| 520 | |a CONCLUSIONS: In a multicentre study, penetrating CD and extensive UC were risk factors for cancer overall. Cancer incidence was higher in CD than in UC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a cancer risk | |
| 650 | 4 | |a phenotype | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Armuzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Scribano, Maria Lia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Inca, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Castiglione, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Papi, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Angelucci, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Daperno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Mocciaro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Riegler, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Fries, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Meucci, Gianmichele |e verfasserin |4 aut | |
| 700 | 1 | |a Alvisi, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Spina, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ardizzone, Sandro |e verfasserin |4 aut | |
| 700 | 1 | |a Petruzziello, Carmelina |e verfasserin |4 aut | |
| 700 | 1 | |a Ruffa, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Kohn, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Vecchi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Guidi, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Di Mitri, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Renna, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Emma, Calabrese |e verfasserin |4 aut | |
| 700 | 1 | |a Rogai, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Ambrogio |e verfasserin |4 aut | |
| 700 | 1 | |a Pallone, Francesco |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Group for the study of Inflammatory Bowel Disease |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 10(2016), 8 vom: 15. Aug., Seite 913-24 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2016 |g number:8 |g day:15 |g month:08 |g pages:913-24 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjw048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2016 |e 8 |b 15 |c 08 |h 913-24 | ||